EU Pharma Strategy To Balance Innovation Incentives & Competition
Stakeholders Have Different Views On ‘Unmet Medical Need’
Delegates at this week’s TOPRA conference heard the European Commission’s “holistic” vision of what it would like to achieve through its pharmaceutical strategy, including incentives for innovation, security of the supply chain, product shortages, real world evidence and big data, and the availability and affordability of medicines.
You may also be interested in...
The European medicines network needs to quickly build up its capabilities in the area of data analysis and digital transformation, but finding the necessary staff is difficult in the face of stiff competition from both the pharmaceutical industry and the likes of Google and Facebook, according to the head of the Danish regulator.
Ambitious efforts to make the EU more resilient to future challenges, such as health threats, drug supply problems, scientific advances and growing medicine costs, have taken a step forward with the publication of a roadmap for a wide-ranging Pharmaceutical Strategy to be adopted by the European Commission later in the year.
As negotiations between the UK and EU enter a crucial phase, the UK life sciences industry has called for more clarity and guidance on what companies can expect to face at the end of the Brexit transition period.